IMC-P115C

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameIMC-P115C
Drug Alias NameIMC-P-115-CPRAME-HLE-A02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > T cell engagers
Mechanisms of ActionImmunologic cytotoxicityT lymphocytes stimulantsMelanoma antigen preferentially expressed in tumors modulators +[4] 
TargetsMelanoma antigen preferentially expressed in tumorsT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsUterine Neoplasms +[12] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryItalyAustraliaUnited Kingdom +[5] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunocore Holdings PLC
China Registration ClassN/A

Develop Information

Active CompaniesImmunocore Holdings PLCImmunocore Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursEndometrial NeoplasmsUterine Neoplasms +[12] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A